An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

Trial Profile

An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Lenvatinib (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Study 205
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 27 Mar 2017 According to an Eisai Co Ltd media release, based on the data from this study, German Federal Joint Committee (G-BA) has confirmed the additional benefit of lenvatinib in combination with everolimus for the treatment of adults with advanced RCC versus everolimus alone.
    • 19 Dec 2016 This trial has been completed in Spain according to European Clinical Trials Database record.
    • 17 Oct 2016 Results published in Eisai media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top